Work

High Degree of Tolerability for Monotherapy With High Doses of Quetiapine

Year: 2002

Type: article

Abstract: Article AbstractLetter to the EditorSir: Quetiapine is a relatively new third-generation antipsychotic with a labeled dose range of 400 to 800 mg/day. Quetiapine has demonstrated efficacy in the management of patients with a history of partial response to conventional antipsychotics. We report the case of a schizophrenic woman who achieved full clinical remission without significant side effects with a high dose of quetiapine (1600 mg/day). To our knowledge, evidence from daily clinical practice or controlled clinical trials has never been published on high doses of this new antipsychotic.

Source: The Journal of Clinical Psychiatry

DOI: 10.4088/jcp.v63n1116g

Authors: Julio Bobes, Maria P. Garcia-Portilla, Pilar A. Saiz, Maria-Teresa Bascaran, Manuel Bousono, Celso Arango

Institutions: Universidad de Oviedo, McGill University Health Centre, Hospital General Universitario Gregorio Marañón

Language: English

Topic: Schizophrenia research and treatment

Subfield: Psychiatry and Mental health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Eli Lilly and Company, Pfizer, AstraZeneca, Eli Lilly Canada